As reported in Drugs.com, on November 2, 2018, the US Food and Drug Administartion approved a new formulation of clobazam for use in patients with the seizure disorder, Lennox-Gastaut syndrome (LGS).   The new product from Aquestive Therapeutics, Inc., which will be marketed under the brand name Sympazan, is in an oral film formulation for patients 2 years of age or older.  Patients with LGS, a severe form of epilepsy, often struggle with swallowing oral dosage forms, including previously available clobazam products such as Onfi.   Sympazan oral film will be berry flavored and offered in 5 mg, 10 mg, and 20 mg dosage units.

Reference

For more information on this new approval, click here.

Additional information about clobazam can be found in the Top 300 Pharmacy Drug Cards or the Top 100 Nonprescription Drug Cards.  If you or your institution subscribes to AccessPharmacy, use or create your MyAccess Profile to sign-in to the Flash Card section.  If your institution does not provide access, ask your medical librarian about subscribing.

For a chance to win GREAT prizes and learn more about medications in the Top 300, check out the Drug Card Scavenger Hunt page on AccessPharmacy. Follow us to receive email alerts when new Drug of the Week and Drug Card Scavenger Hunt updates are posted.